

OSNA – Advanced platform for analysing lymph nodes




OSNA is an automated molecular diagnostic assay that uses a rapid nucleic acid amplification technology (RT-LAMP*) to quantify Cytokeratin 19 (CK19) mRNA expression. CK19 is an epithelial cell marker and normally not present in lymph node tissue. The amount of CK19 mRNA expression correlates with the size of metastatic foci and so gives a clear indication of the metastatic tumour burden in the lymph nodes. This in turn allows precise staging – the prerequisite for further decision-making.

The platform for performing OSNA is a compact device. It is easy to handle in a smooth process so that it demands few resources. Lymph node tissue from different patients or cancer types can be processed in parallel, delivering results of up to 14 lymph nodes in a single run. If needed, it can provide quick results in an intraoperative setting.

At a glance


- Quantitative determination of the metastatic burden by measurement of CK19 mRNA expression as marker
- Standardised and reliable results thanks to whole node analysis
- Short TAT (~15 min 1 sample, ~30 min 14 samples) – most of it as walk-away time
- Fast availability of results
- High flexibility (multi-application / patient usage)
- Reagent kit concept adapted to different potential needs
- Simple reagent management and traceability of consumption by QR Code identification
- Easy to operate, user-friendly integrated touch screen
- Easy integration into a quality controlled laboratory environment
- Designed to meet state-of-the-art regulatory and quality requirements
- CE-marked for application in

- Breast cancer
- Colon cancer
- Gastric cancer



CK19

* RT-LAMP = Reverse transcriptase loop-mediated isothermal amplification; licensed under the agreement with Eiken Chemical CO., LTD




Key specifications

Model	Gene Amplification Detector RD-210
Method	OSNA (One Step Nucleic Acid Amplification)
Diagnostic Parameter	CK19 mRNA
Sample loading capacity	up to 14 samples
Throughput	1 sample / batch: within 16 min 14 samples / batch: within 30 min
Dimensions / weight w x h x d [mm / kg]	600 x 610 x 780 / approx. 90

OSNA – Revealing the whole picture


More differentiated information – Supporting better treatment decisions



OSNA – More accurate lymph node analysis for individualised patient treatment

Metastatic spread to lymph nodes is one of the most important prognostic factors in most cancers and one of the TNM classification parameters. The nodal status is a significant parameter that helps clinicians to decide on the most appropriate surgical procedure and subsequent therapy steps. The precise assessment of lymph node tissue, and determining metastatic burden, is therefore decisive for providing high diagnostic quality, enabling reliable staging.

Routine practice in histopathology analyses only a limited amount of tissue and can therefore provide only limited information. Since methodologies differ across institutions, standardisation of results is also a challenge.



OSNA

The optimal way to gain an understanding of a node's metastatic burden is to analyse the entire node. This leaves no room for interpretation and can provide information beyond the conventional classification of micro- and macrometastases.

OSNA – or One Step Nucleic Acid Amplification – is the first commercially available product providing quantitative information about the metastatic burden in lymph nodes!

OSNA has already proven its utility in recent years and is a well-established method in routine in many clinical facilities. Clinicians and patients have experienced the benefits of

- a highly accurate and comprehensive lymph node examination
- the prompt availability of results
- the high value of information that is delivered to them
- reduced waiting times in worries after surgery

Please visit our website for more information: www.sysmex-europe.com

